

# Migraine prevention in the real world: Exploring the role of anti-CGRP antibodies



# Disclaimer

- *Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions*
- *The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use*
- *No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities*
- *touchIME accepts no responsibility for errors or omissions*

# Recognizing the burden of migraine in daily life

## Ms Elena Ruiz de la Torre

Patient Advocate and Executive Director  
European Migraine & Headache Alliance  
Valencia, Spain





**Can you outline some of the challenges people living with migraine face in daily life?**

# Burden of migraine



57% of patients experience >8 days of migraine per month\*<sup>†</sup>

**Migraine days<sup>1</sup>**



Impact on relationships, family life and family planning decisions

**Relationships and family<sup>1,2</sup>**



Impact on self-reported overall health

**Overall health<sup>2</sup>**




Sense of isolation and exclusion from society

**Stigma<sup>1,3</sup>**



Work productivity is an important quality of life need\*

**Work life<sup>1</sup>**




52% report treatment costs impact finances<sup>‡</sup>

**Finances<sup>1</sup>**

\*Data from the European Migraine & Headache Alliance and KPMG "Access To Care III" survey of migraine patients from 41 different countries. 58% of the responses correspond to EU5 countries (Spain, Italy, France, Germany and UK); <sup>†</sup>survey results from 2,831 respondents; <sup>‡</sup>survey results from 2,326 respondents.

1. European Migraine & Headache Alliance. 2021. Available at: [www.emhalliance.org/wp-content/uploads/ATC-EMHA-Dossier.pdf](http://www.emhalliance.org/wp-content/uploads/ATC-EMHA-Dossier.pdf) (accessed 22 May 2023);

2. Buse DC, et al. *Headache*. 2019;59:1286–99; 3. Seng EK, et al. *Headache*. 2022;62:1354–64.


The background features a large, light gray globe with a grid of latitude and longitude lines on the right side. On the left side, there is a vertical line of seven orange dots of varying sizes, with a white circular arc partially visible behind them. The entire slide is framed by a solid orange border.

**What about the longer term -  
does migraine get worse  
over time?**

# Migraine progression

Inadequate treatment of episodic migraine increases the risk of developing chronic migraine<sup>1</sup>

## Progression of migraine



## Comorbidities associated with chronic migraine



Respiratory diseases<sup>2</sup>



Cardiovascular diseases<sup>2</sup>



Chronic neck and back pain<sup>3</sup>



Anxiety and depression<sup>3</sup>

# Risk factors for migraine progression

## Patient characteristics



Female sex<sup>1,2</sup>



Low educational status<sup>1</sup>



Stressful life events<sup>1</sup>

## Comorbidities



Obesity<sup>1,2</sup>



Depression<sup>1,2</sup>



Anxiety<sup>1,2</sup>

## Clinical factors




Acute medication overuse<sup>1,2</sup>



Ineffective acute treatment<sup>1,2</sup>






**How important is timely and accurate diagnosis as the first step toward effective treatment, and what factors can support this?**

# Diagnosis of migraine


## Suspicious signs and symptoms

- Recurrent headache of moderate to severe intensity
- Visual aura
- Family history of migraine
- Onset of symptoms at or around puberty



## Patient centricity

- Provide appropriate reassurance
- Agree on realistic objectives
- Identify predisposing and/or trigger factors
- Follow strategy to individualize therapy according to symptoms and needs
- Awareness campaigns by patient associations, e.g. EMHA

The background of the slide features a large, light gray globe with a grid of latitude and longitude lines. Scattered around the globe are several orange dots of varying sizes, some of which are partially obscured by the text. The overall aesthetic is clean and professional, with a white background and an orange border at the bottom.

**From patients' perspectives,  
what impact do you think  
anti-CGRP antibodies have had  
in terms of providing options  
for preventative treatment  
of migraine?**

# European patient perspective on anti-CGRP antibodies



## Awareness

**62%** of patients know about anti-CGRPs<sup>1\*†</sup>



## Barriers to access

Not mentioned by doctors: **26%**<sup>1\*†</sup>

Not covered by health system: **25%**<sup>1\*†</sup>



## Clinical response

**54% to 63%** throughout first 6 months<sup>2§</sup>



## Satisfaction

**77%** of patients report improvement or satisfaction<sup>3</sup>

\*Data from the European Migraine & Headache Alliance and KPMG “Access To Care III” survey of migraine patients in 41 countries. 58% of responses were from EU5 countries (Spain, Italy, France, Germany and UK); †based on 1,672 respondents; ‡based on 1,119 respondents; §data from observational study of patients receiving monthly migraine treatment with galcanezumab (n=49), fremanezumab (n=19) and erenumab (n=84). Responders defined as those with 50–100% headache day reduction vs baseline.

1. European Migraine & Headache Alliance. 2021. Available at: [www.emhalliance.org/wp-content/uploads/ATC-EMHA-Dossier.pdf](http://www.emhalliance.org/wp-content/uploads/ATC-EMHA-Dossier.pdf) (accessed 22 May 2023);

2. Schiano di Cola F, et al. *Eur J Neurol*. 2023;30:1764–73;

3. European Migraine & Headache Alliance. 2021. Available at: [www.emhalliance.org/project/access-to-care-survey-2021/](http://www.emhalliance.org/project/access-to-care-survey-2021/) (accessed 2 June 2023).